Premium
A double‐blind comparative study of remoxipride and haloperidol in schizophrenic and schizophreniform disorders
Author(s) -
Mendlewicz J.,
Bleeker E.,
Cosyns P.,
Deleu G.,
Lotstra F.,
Masson A.,
Mertens C.,
Parent M.,
Peuskens J.,
Suy E.,
Wilde J.,
Wilmotte J.,
Nörgard J.
Publication year - 1990
Publication title -
acta psychiatrica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.849
H-Index - 146
eISSN - 1600-0447
pISSN - 0001-690X
DOI - 10.1111/j.1600-0447.1990.tb05306.x
Subject(s) - haloperidol , extrapyramidal symptoms , schizophreniform disorder , tolerability , placebo , psychology , anesthesia , akathisia , medicine , antipsychotic , psychiatry , schizophrenia (object oriented programming) , psychosis , adverse effect , schizoaffective disorder , dopamine , alternative medicine , pathology
The antipsychotic effect of remoxipride was compared to that of haloperidol in a randomized double‐blind study with parallel group design comprising 98 patients with schizophrenia or schizophreniform disorder according to DSM‐III. After a 3–7 day placebo washout period, patients received either 150–600 mg of remoxipride or 5–20 mg of haloperidol daily for 6 weeks. No significant differences in efficacy were found between the two treatments. Treatment‐emergent checklist symptoms such as hypokinesia, rigidity, and tremor occurred more frequently and were more severe during haloperidol than during remoxipride treatment despite a significantly higher concurrent use of anticholinergic drugs in the haloperidol group. Haloperidol‐treated patients reported greater increases in sleep and salivation than remoxipride‐treated patients. Shoulder shaking and tremor were reported as occurring more frequently in the haloperidol group according to the Simpson and Angus rating scale for extrapyramidal symptoms. In summary, the two drugs seemed to be equally efficacious, though the tolerability profile favoured remoxipride.